SFX by Ex Libris Inc.

Title:	RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Source:	Nature [0028-0836] Poulikakos, P I yr:2010

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Stokoe, G. "RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth." Nature 464.7287 (2010): 431-435.
description	2.	Halaban, R. "PLX4032, a Selective BRAF(V600E) Kinase Inhibitor, Activates the ERK Pathway and Enhances Cell Migration and Proliferation of BRAF(WT) Melanoma Cells." Pigment cell & melanoma research 23.2 (2010): 190-200.
description	3.	Flaherty, Keith T. "Inhibition of Mutated, Activated BRAF in Metastatic Melanoma." New England Journal of Medicine 363.9 (2010): 809-819.
description	4.	Poulikakos, Poulikos I. "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)." Nature 480.7377 (2011): 387-390.
description	5.	Apsel, Beth h. "Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases." Nature chemical biology 4.11 (2008): 691-699.
description	6.	Heidorn, A. "Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF." Cell 140.2 (2010): 209-21.
description	7.	Hong, David S S. "Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib." Archives of dermatology 144.6 (2008): 779-82.
description	8.	Chapman, Paul B. "Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation." The New England journal of medicine 364.26 (2011): 2507-2516.
description	9.	Bollag, Hirth P. "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma." Nature 467.7315 (2010): 596-599.
description	10.	Cichowski, K. "Drug discovery: inhibitors that activate." Nature 464.7287 (2010): 358-359.
description	11.	Koya, Richard C. "Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses." Proceedings of the National Academy of Sciences of the United States of America 107.32 (2010): 14286-14291.
description	12.	Maemondo, M. "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR." New England Journal of Medicine, The 362.25 (2010): 2380-2388.
description	13.	Adzhubei, Ivan A. "A method and server for predicting damaging missense mutations." Nature Methods 7.4 (2010): 248-249.
description	14.	Garber, K. "Cancer research. Melanoma drug vindicates targeted approach." Science 326.5960 (2009): 1619-1619.
description	15.	Richly, H. "Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial." European journal of cancer 45.4 (2009): 579-87.
description	16.	Brana, Miguel F. "Synthesis and biological activity of N,N-dialkylaminoalkyl-substituted bisindolyl and diphenyl pyrazolone derivatives." Bioorganic & medicinal chemistry 14.1 (2006): 9-4650.
description	17.	Lundeberg, J. "NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing." Melanoma research 16.6 (2007): 471-8.
description	18.	Mihm, Arlo J C. "Melanoma." The New England journal of medicine 355.1 (2006): 51-65.
description	19.	Kolch, W. "Coordinating ERK/MAPK signalling through scaffolds and inhibitors." Nature reviews. Molecular cell biology 6.11 (2005): 827-37.
description	20.	Buzko, Oleksandr V V. "Modified AutoDock for accurate docking of protein kinase inhibitors." Journal of computer-aided molecular design 16.2: 113-127.